Afatinib in advanced NSCLC: a profile of its use

Afatinib [Giotrif(®) (EU); Gilotrif(®) (USA)] is an orally administered, irreversible inhibitor of the ErbB family of tyrosine kinases that provides an important first-line treatment option for advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutati...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Drugs Ther Perspect
Main Authors: Deeks, Emma D., Keating, Gillian M.
Format: Artigo
Sprog:Inglês
Udgivet: Springer International Publishing 2018
Fag:
Adis Drug Q&A
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5840214/
https://ncbi.nlm.nih.gov/pubmed/29540977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40267-018-0482-6
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker